Alan J. Thompson ET AL: "Multiple sclerosis" In: "Outcomes in Neurological and Neurosurgical Disorders", 9 April 1998 (1998-04-09), Cambridge University Press, XP055711180, ISBN: 978-0-511-52694-7 pages 239-266, DOI: 10.1017/CBO9780511526947.015, (B1)

FRAN?OIS CURTIN ET AL: "GNbAC1, a Humanized Monoclonal Antibody Against the Envelope Protein of Multiple Sclerosis-Associated Endogenous Retrovirus: A First-in-Humans Randomized Clinical Study", CLINICAL THERAPEUTICS, vol. 34, no. 12, 1 December 2012 (2012-12-01), pages 2268-2278, XP055204753, ISSN: 0149-2918, DOI: 10.1016/j.clinthera.2012.11.006 (B1)

KREMER DAVID ET AL: "The Complex World of Oligodendroglial Differentiation Inhibitors", ANNALS OF NEUROLOGY, vol. 69, no. 4, April 2011 (2011-04), pages 602-618, XP002716523, (B1)

WO-A2-2008/096271 (B1)

SORMANI MARIA PIA ET AL: "Assessing Repair in Multiple Sclerosis: Outcomes for Phase II Clinical Trials", NEUROTHERAPEUTICS, ELSEVIER INC, US, vol. 14, no. 4, 10 July 2017 (2017-07-10), pages 924-933, XP036543197, ISSN: 1933-7213, DOI: 10.1007/S13311-017-0558-3 [retrieved on 2017-07-10] (B1)

U.S. National Library of Medicine: "Safety Study of GNbAC1 in Multiple Sclerosis Patients NCT01639300", ClinicalTrials.gov , 12 July 2012 (2012-07-12), XP002786263, Retrieved from the Internet: URL:https://clinicaltrials.gov/ct2/show/NC T01639300?id=NCT01639300&rank=1&load=cart [retrieved on 2018-11-06] (B1)

WO-A1-2010/003977 (B1)

LANG ALOIS B ET AL: "The therapeutic potential of monoclonal anti-human endogenous retrovirus W (HERV-W) envelope protein antibody in multiple sclerosis: Results from a new EAE-animal model", HUMAN ANTIBODIES, IOS PRESS, AMSTERDAM, NL, vol. 17, no. 1-2, 12 November 2008 (2008-11-12), page 21, XP009124418, ISSN: 1093-2607 (B1)